Browsing by Author Anglesio, Michael S.

Jump to: 0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
or enter first few letters:  
Showing results 1 to 4 of 4
Issue DateTitleAuthor(s)Citation
2011Deregulation of MYCN, LIN28B and LET7 in a Molecular Subtype of Aggressive High-Grade Serous Ovarian CancersdeFazio, Anna; Anglesio, Michael S.; Cowin, Prue; et al, various; Etemadmoghadam, Dariush; George, Joshy; Helland, Aslaug; House, Colin; Johnstone, Cameron; Melnyk, Nataliya; Rustgi, Anil K.; Sheppard, Karen; Western Clinical School: Westmead Millennium InstituteDeregulation of MYCN, LIN28B and LET7 in a Molecular Subtype of Aggressive High-Grade Serous Ovarian Cancers, PLoS One, vol.6, 4, 2011,pp Article number e18064-1-Article number e18064-9
2014Genomic classification of serous ovarian cancer with adjacent borderline differentiates RAS pathway and TP53-mutant tumors and identifies NRAS as an oncogenic driverBalleine, Rosemary; Brand, Alison; Clarke, Christine; deFazio, Anna; Emmanuel, Catherine; Harnett, Paul; Hogg, Russell; Kennedy, Catherine Jane; Sharma, Raghwa; Wain, Gerard; Anglesio, Michael S.; Chiew, Yoke-Eng; et al, Various; Etemadmoghadam, Dariush; Fereday, Sian; Galletta, Laura; George, Joshy; Hung, Jillian A.; MacConaill, Laura; Palescandolo, Emanuele; Russell, P; Western Clinical School: Westmead Millennium Institute; Western Clinical School: Medicine (Westmead); Western Clinical School: Westmead Millennium Institute; Western Clinical School: Westmead Millennium Institute; Western Clinical School: Westmead Millennium Institute; Western Clinical School: Medicine (Westmead); Western Clinical School: Medicine (Westmead); Western Clinical School: Medicine (Westmead); Western Clinical School: Pathology; Western Clinical School: Obstetrics & GynaecologyGenomic classification of serous ovarian cancer with adjacent borderline differentiates RAS pathway and TP53-mutant tumors and identifies NRAS as an oncogenic driver, Clinical Cancer Research, vol.20, 24, 2014,pp 6618-6630
2011IL6-STAT3-HIF Signaling and Therapeutic Response to the Angiogenesis Inhibitor Sunitinib in Ovarian Clear Cell CancerdeFazio, Anna; Anglesio, Michael S.; Australian Ovarian Cancer Study Group, (AOCSG); Balkwill, Frances; Birrer, Michael J.; Bowtell, David D L; Campbell, Ian G.; Chakravarty, Probir; Coward, Jermaine; Cowin, Prue; Friedlander, Michael L.; George, Joshy; Gilks, B; Gorringe, Kylie; House, Colin; Huntsman, David; Kalloger, Steve; Kulbe, Hagen; Lemech, Charlotte; Okamoto, Aikou; Power, Jeremy; Rischin, D.; Western Clinical School: Westmead Millennium InstituteIL6-STAT3-HIF Signaling and Therapeutic Response to the Angiogenesis Inhibitor Sunitinib in Ovarian Clear Cell Cancer, Clinical Cancer Research, vol.17, 8, 2011,pp 2538-2548
2008Mutation of ERBB2 provides a novel alternative mechanism for the ubiquitous activation of RAS-MAPK in ovarian serous low malignant potential tumors.deFazio, Anna; Russell, Peter; Anglesio, Michael S.; Arnold, Jeremy; Australian Ovarian Cancer Study Group, (AOCSG); Birrer, Michael J.; Bowtell, David D L; Chenevix-Trench, Georgia; Fereday, Sian; George, Joshy; Locandro, Bianca; Sharma, Raghwa; Simms, Lisa; Tinker, A. V.; Tothill, Richard W.; Traficante, Nadia; Waddell, Nic; Western Clinical School: Westmead Millennium Institute; Central Clinical School: PathologyMutation of ERBB2 provides a novel alternative mechanism for the ubiquitous activation of RAS-MAPK in ovarian serous low malignant potential tumors., Molecular Cancer Research, vol.6, 11, 2008,pp 1678-1690